莫西沙星治疗老年人性社区获得性肺炎的疗效分析

On Clinical Efficacy of Moxifloxacin in the Treatment of Elderly Community-acquired Pneumonia

目的探讨莫西沙星治疗老年人的社区获得性肺炎(CAP)的临床疗效及安全性。方法按入院先后顺序,将70例老年人的CAP患者随机分为观察组与对照组,每组35例。观察组给予莫西沙星400mg,静脉滴注qd;对照组给予左氧氟沙星400mg静脉滴注qd。疗程为2周。观察临床疗效及其不良反应。结果两组的有效率分别为90%和70%,组间比较差异有统计学意义(P<0.05);两组的细菌清除率分别为94.3%和71.4%,组间比较差异无统计学意义(P>0.05)。在药物相关的不良反应,患者对两者的耐受较好,安全性相当。结论莫西沙星治疗老年CAP疗效显著,值得临床推广应用。

Objective To explore the clinical efficacy and safety of moxifloxacin in the treatment of elderly community-acquired pneumonia （CAP）. Methods According to their admission orders, 70 elderly patients with CAP were randomly divided into the observation group and the control group （n= 35 ）. The observation group was given 400 mg moxifloxacin by intravenous drip qd; the control group was given 400 mg levofloxacin by intravenous drip qd. The treatment lasted for 2 weeks. Clinical effects and adverse reactions were observed. Results The clinical efficacy rates were 90% and 70%, respectively. The difference was statistically significant between the two groups （P〈 0.05） ; the bacterial clearance rates among the two groups were 94.30/00 and 71.4% ,and the difference was not statistically significant between the groups （P 〉 0.05）. In drug-related adverse reactions, patients had good tolerance to both injections. Conclusions The clinical efficacy of moxifloxacin is significant in the treatment of senile CAP, worthy of clinical application..